Matrix-Bio, Purdue University ink option agreement
FORT WAYNE, Ind.—Diagnostics company Matrix-Bio Inc. and the Purdue Research Foundation have signed an exclusive agreement optioning metabolite biomarker technology as well as eight patent applications to determine the commercial potential of cancer diagnostics tests based on said technologies. No financial terms were released, but the agreement is slated for one year with an option for an extension. The technologies include metabolite biomarkers for detecting esophageal, liver, pancreatic and colon cancer, as well as metabolite biomarkers for identifying liver cancer in hepatitis C patients and biomarkers for predicting preoperative chemotherapy effectiveness for breast cancer treatment. This agreement builds on an existing master license agreement between the two organizations for breast cancer biomarkers and metabolite profiling technology developed by Dan Raftery, founder and chief scientific officer of Matrix-Bio.